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Abstract: We examined the potential risks and beneﬁ  ts of switching from olanzapine to 
quetiapine in mentally stable, obese, or overweight patients with schizophrenia or schizoaf-
fective disorder. Patients receiving olanzapine were randomized to continuing olanzapine 
treatment (N = 68; 7.5–20 mg/day) or switching to quetiapine (N = 65; 300–800 mg/day). Time 
to relapse was the primary study objective; secondary objectives included changes in weight, 
metabolic parameters, and psychiatric symptoms, and discontinuation rates. No signiﬁ  cant dif-
ference in time to relapse was observed (p = 0.293), but signiﬁ  cantly more patients remained 
on treatment in the olanzapine group compared with the quetiapine group (70.6% vs 43.1%; 
p = 0.002). Olanzapine-treated patients had signiﬁ  cantly lower rates of study discontinuation 
for lack of efﬁ  cacy and psychiatric adverse events (AEs) compared to quetiapine (2.94% vs 
15.38%, p = 0.015). Signiﬁ  cantly more patients in the olanzapine group experienced an increase 
in BMI  1 kg/m2. Olanzapine-treated patients experienced signiﬁ  cantly greater increases in 
weight from Weeks 2 through 13. Switching patients with stable disease from olanzapine to 
quetiapine did not signiﬁ  cantly shorten time to relapse, but produced more frequent study 
discontinuations due to lack of efﬁ  cacy or psychiatric AEs with moderate but variable improve-
ment in weight and no signiﬁ  cant between-group differences in mean changes in metabolic 
laboratory parameters.
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Introduction
Continuous treatment with antipsychotic medication is essential for stabilization 
and prevention of relapse in patients with schizophrenia. Poor patient compliance 
undermines therapeutic success and increases the risk of hospitalization (Weiden 
et al 2004). Unfortunately, only about 50% of all patients receiving treatment 
for schizophrenia adhere to their prescribed medication regimens (Cramer and 
Rosenheck 1998).
Currently olanzapine, a second-generation, atypical antipsychotic drug, is one of 
the commonly used medications for the treatment of schizophrenia. Compared with 
other conventional and atypical antipsychotics, olanzapine has been associated with 
longer time to discontinuation due to any cause (Ascher-Svanum et al 2006; Essock 
et al 2006; Beasley et al 2007), which is an index thought to reﬂ  ect both efﬁ  cacy and 
tolerability of an antipsychotic medication. However, clinically signiﬁ  cant weight 
gain has been frequently reported during olanzapine treatment (Kinon et al 2005). 
To avoid the potential consequences of clinically signiﬁ  cant weight gain, some clini-
cians advocate proactive switching of stable patients from olanzapine to quetiapine, Therapeutics and Clinical Risk Management 2008:4(4) 714
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as this strategy has been associated with reductions in weight 
(Gupta et al 2004).
Switching antipsychotic medications may be one 
approach to lessen potential safety concerns in patients who 
have experienced treatment-emergent weight gain, but the 
impact of switching on psychiatric symptoms is less clear. 
The purpose of this study was to gain better understanding 
of potential risks and beneﬁ  ts associated with switching from 
olanzapine to quetiapine in stable patients with schizophrenia 
or schizoaffective disorder.
Materials and methods
This study was conducted in 26 centers in the US. The 
study protocol was reviewed and approved by individual 
institutional review boards prior to enrolling any patients, 
and was conducted in conformity with the US Food and 
Drug Administration Code of Federal Regulations (21 CFR, 
Part 50), and the Declaration of Helsinki and its amendments. 
The study was consistent with Good Clinical Practices and all 
applicable regulatory requirements. All participants provided 
written informed consent before receiving any study therapy 
or undergoing any study procedure. The study was conducted 
between July 2004 and March 2006.
Patients
Males and females between 18 and 75 years of age and 
diagnosed with schizophrenia or schizoaffective disorder 
according to the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DSM-IV) were enrolled 
in this study. Important inclusion criteria included: a con-
ﬁ  rmed psychotic episode within the last 5 years prior to 
enrollment; clinically stable for at least 15 days on a ﬁ  xed 
dose of olanzapine (10–20 mg/day) prior to enrollment; 
obese (body mass index [BMI]  30 kg/m2) or overweight 
(BMI  25 kg/m2 and  30 kg/m2) with at least one cardio-
vascular risk factor (diabetes mellitus or impaired fasting 
glucose, dyslipidemia, elevated blood pressure, or waist 
circumference  102 cm for men or  88 cm for women). 
Patients were to be free of any other signiﬁ  cant medical 
illness at enrollment. In general, concomitant medications 
with primary central nervous system activity were not 
allowed in this protocol.
Study design
This multicenter trial utilized a 2-phase, randomized, 
double-blind, ﬂ  exible-dosed, parallel-group design. Eli-
gible and consenting patients were randomly assigned 
to receive olanzapine (7.5–20 mg/day) or quetiapine 
(300–800 mg/day). During the first (double-blind, 
cross-titration) phase, patients randomized to the olan-
zapine group maintained their original dose while patients 
randomized to the quetiapine group had their olanzapine 
dose gradually decreased (and completely discontinued by 
Day 7) as their quetiapine dose was gradually increased. 
During the second (double-blind, ﬂ  exible-dose) phase, 
doses could be adjusted within a range from 7.5 mg/day to 
20 mg/day for olanzapine or 300 mg/day to 800 mg/day for 
quetiapine depending on patient symptoms and tolerance. 
Treatment was to continue for 24 weeks, followed by a 
1-week titration phase to open-label treatment at the end 
of the study. Over the 26 weeks total length of the study, 
14 visits were scheduled for each patient; 12 of those visits 
occurred during the blinded study period with increasing 
time intervals between visits (3 visits 1 week apart, 2 visits 
2 weeks apart, and 7 visits 3 weeks apart).
Efﬁ  cacy and safety assessments
The primary study objective was time to relapse based on 
change in Positive and Negative Syndrome Scale (PANSS) 
(Kay et al 1987), the Clinical Global Impression of Sever-
ity (CGI-S) (Guy 1976) scale, or the level of psychiatric 
care. Relapse was deﬁ  ned as the occurrence of at least 1 of 
the following 3 events: hospitalization due to psychiatric 
reasons;  20% worsening on the PANSS total score and 
an increase in the level of care for psychiatric reasons 
compared to baseline;  20% worsening of PANSS total 
score and worsening of CGI-S by at least 1 level com-
pared with baseline and CGI-S score of  4. Secondary 
objectives included assessment of time to discontinuation, 
changes in weight, BMI, and metabolic parameters, and 
the incidence of treatment-emergent adverse events. The 
protocol speciﬁ  ed to group discontinuations due to lack 
of efﬁ  cacy and adverse psychiatric events together in the 
analysis, as treatment-emergent psychiatric adverse events 
are in the majority of the cases based on efﬁ  cacy problems 
and not on tolerance problems (Liu-Seifert et al 2005; 
Perkins et al 2007). PANSS and CGI-S were administered 
at every visit.
Safety evaluations included the assessment of vital signs 
and weight, recording of adverse events, and review of treat-
ment compliance at every visit. A physical examination, mea-
surement of height and waist circumference, and an extensive 
interview to capture the patient’s psychiatric and medical his-
tory were performed at the ﬁ  rst visit. Laboratory tests (clinical 
chemistry, hematology, hepatitis, drug screen, pregnancy, TSH, 
prolactin, hemoglobin A1c [HbA1c], lipid panel, and insulin) Therapeutics and Clinical Risk Management 2008:4(4) 715
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were performed at Visit 1, and selected laboratory tests (clinical 
chemistry, hematology, prolactin, HbA1c, lipid panel, and 
insulin) were repeated throughout the study.
Statistical analysis
In the original power calculations, a sample size of approxi-
mately 200 patients per treatment group was established in 
order to detect a difference of 15% in rates of relapse by 
Week 24 with a power of 80%–85% and 5% type I error for 
a 2-sided log rank test. Due to recruitment difﬁ  culties, only 
133 patients (olanzapine, 68; quetiapine, 65) were enrolled, 
which yielded a reduced power of 37%–40% to detect a 15% 
difference using the same assumptions. The ﬁ  nal sample size 
provided 80% power to detect a 1.0 kg/m2 difference in BMI 
(29% for a 0.5 kg/m2 difference) and 99% power to detect a 
treatment difference of 0.4% change in HbA1c.
The primary study objective was assessed using a log-rank 
test for differences over time in relapse for olanzapine vs que-
tiapine. Rates of study discontinuation by treatment group were 
compared using Fisher’s exact test. Both the distribution of time 
to relapse and the survival distributions for time to discontinua-
tion were evaluated within each group using the Kaplan-Meier 
product limit estimator. Treatment differences in the survival 
distribution were assessed using the log-rank test.
Treatment differences in categorical safety variables 
(occurrence of treatment-emergent adverse events, vital 
signs, rates of study discontinuation) were evaluated with 
Fisher’s exact test. Analysis of variance (ANOVA) or 
analysis of covariance (ANCOVA) methods were used on 
rank changes for laboratory parameters (or raw changes for 
weight and BMI) from baseline to last observation carried 
forward (LOCF) endpoints, with terms for categorical effects 
of treatment and center in the model, and also adjusted for 
differences in baseline levels (included as a continuous score 
for weight and BMI or as a class variable, based on quintiles 
of baseline score, for laboratory parameters). Signiﬁ  cance of 
changes from baseline in laboratory parameters and weight 
were evaluated with a nonparametric Wilcoxon signed-rank 
test. The cut-offs for clinically signiﬁ  cant changes in weight 
and BMI were determined a priori in the study protocol.
Time course and treatment differences for changes in 
weight, BMI, and PANSS total scores were evaluated using 
mixed effects repeated measures analysis (MMRM) with 
categorical effects of treatment, investigator, duration of 
treatment, treatment by time interaction and continuous 
baseline score, and baseline score by time interaction. Cor-
relation in repeated measures was modeled with unstructured 
covariance.
To evaluate the potential effect of differences in certain 
baseline covariates (BMI and PANSS) on treatment differ-
ences in categorical safety variables (categorical changes 
in BMI and weight, and study discontinuation), additional 
analyses were conducted using a “stratiﬁ  ed version” of 
Fisher’s exact test. Speciﬁ  cally, we used an exact permutation 
test for comparing a categorical outcome across 2 treatment 
groups, stratiﬁ  ed by baseline covariate (BMI or PANSS, 
depending on the outcome). Strata were deﬁ  ned by quintiles 
of the baseline covariate.
Efﬁ  cacy and safety analyses included all randomized 
patients who had at least 1 post-baseline evaluation for a 
given analysis. All tests of treatment effects were performed 
at a 2-sided alpha level of 0.05, and no adjustments for 
multiplicity were made. All statistical computations were 
performed using SAS (SAS®) software Version 8.2 (SAS 
Institute, Inc., Cary, NC, USA).
Results
Patients
A total of 133 patients were randomly assigned to continu-
ing therapy with olanzapine (N = 68; mean modal dose: 
16.9 mg/day) or a switching of treatment to quetiapine 
(N = 65; mean modal dose: 439.7 mg/day). Baseline patient 
characteristics were similar for both treatment groups (eg, 
olanzapine vs quetiapine, respectively: mean age (years) 
[standard deviation (SD)]: 45.4 [9.4] vs 42.5 [11.5]; p = 0.083; 
mean time on olanzapine (weeks) [SD]: 67.5 [98.5] vs 
69.4 [107.8]; p = 0.554). At baseline, there were statistically 
signiﬁ  cant differences between treatment groups (olanzapine 
vs quetiapine, respectively) in PANSS total (mean value 
[SD]): 61.1 [17.9] vs 65.9 [20.4]; p = 0.033 and BMI (mean 
value [SD]): 34.6 kg/m2 [7.1] vs 37.5 kg/m2 [8.6]; p = 0.042). 
These differences had occurred by chance in the random 
allocation process.
A signiﬁ  cantly higher proportion of patients in the 
olanzapine group completed the 24 weeks of treatment 
compared to the quetiapine group (70.6% vs 43.1%, 
respectively; p = 0.002). Survival curves demonstrating the 
probability of remaining on assigned treatment are shown 
in Figure 1a.
Efﬁ  cacy endpoints
No signiﬁ  cant differences were observed between the treat-
ment groups in time to relapse (Figure 2) or in the frequency 
of relapses occurring during the study. In the olanzapine 
group, 8 patients met at least 1 of the relapse criteria com-
pared with 10 patients in the quetiapine group (Table 1).Therapeutics and Clinical Risk Management 2008:4(4) 716
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Analysis of the reported reasons for discontinuation 
revealed that discontinuation due to psychiatric adverse 
events, or due to the combination of lack of efﬁ  cacy or 
psychiatric adverse events, was signiﬁ  cantly higher in the 
quetiapine group than in those remaining on olanzapine 
(p = 0.031 and 0.015, respectively; Figure 1b). No signiﬁ  cant 
difference was observed in the frequency of discontinuations 
due to nonpsychiatric adverse events.
Both patients treated with olanzapine and those switched 
to quetiapine experienced improvements in their PANSS total 
scores throughout the course of the study (Figure 3). While 
PANSS scores for patients receiving olanzapine signiﬁ  cantly 
improved from baseline scores at Week 1, the improvement 
for quetiapine patients reached signiﬁ  cance at Week 2. The 
olanzapine group maintained a slight but steady increase in 
improvement through the course of the blinded treatment 
phase. In comparison, the quetiapine group experienced less 
of an improvement which was not persistent throughout the 
blinded treatment phase. At Weeks 13 and 19, improvement 
from baseline was no longer signiﬁ  cant for patients in the que-
tiapine group, and their PANSS total scores were signiﬁ  cantly 
worse than those of patients in the olanzapine group.
Changes in weight, BMI, vital signs, and metabolic 
laboratory parameters
MMRM analysis of the mean changes from baseline to 
endpoint revealed significant increases (p   0.05) for 
weight from Week 1 through Week 16 for patients in 
the olanzapine group (Figure 4a). Weight changes were 
statistically signiﬁ  cant between treatment groups from 
Weeks 2 through Week 13 (p   0.05), with patients in the 
olanzapine group gaining more weight than patients in the 
quetiapine group (Figure 4a). No signiﬁ  cant changes in 
weight were observed for patients in the quetiapine group 
throughout the study or for patients in the olanzapine group 
at the last scheduled visit. The between group differences 
in both categorical weight loss and weight gain (measured 
as a change of  7% from the baseline body weight) did not 
reach statistical signiﬁ  cance.
MMRM analysis of the mean changes from baseline to 
endpoint revealed signiﬁ  cant increases (p   0.05) for BMI 
from Week 1 through Week 13 in the olanzapine group 
(Figure 4b). Signiﬁ  cantly more patients in the olanzapine 
group than in the quetiapine group experienced an increase in 
BMI  1 kg/m2 during treatment with olanzapine compared 
with quetiapine (53.7% vs 33.3%, p = 0.031). No signiﬁ  cant 
between-group difference was observed in the number of 
patients whose BMI decreased  1 kg/m2 during treatment 
with olanzapine compared with quetiapine (30.9% vs 39.3%, 
p = 0.357).
Vital signs showed no significant between group 
differences. Changes in HbA1c were small in both groups 
and the difference was not statistically signiﬁ  cant (olanzap-
ine +0.07%, quetiapine –0.03%). LOCF analysis of the mean 
changes from baseline to LOCF endpoint for weight, BMI, 
fasting glucose, insulin, triglycerides, HDL-cholesterol, 
LDL-cholesterol, or total cholesterol did not demonstrate 
signiﬁ  cant differences between treatment groups (Table 2); 
olanzapine vs quetiapine: weight at baseline (kg) [SD]: 
100.71 [19.7] vs 106.7 [19.9]; mean change in weight to 
LOCF endpoint (kg) [SD]: 0.99 [5.82] vs –0.82 [5.30], 
p = 0.088; BMI at baseline (kg/m2) [SD]: 34.6 [7.1] vs 
37.5 [8.6]; mean change in BMI to LOCF endpoint (kg/m2) 
[SD]: 0.31 [1.94] vs –0.30 [1.90], p = 0.150). Fasting insu-
lin levels were elevated at baseline and did not improve in 
either group.
Figure 1 Patient disposition.
Figure 1a (upper) Time remaining on treatment. Kaplan-Meier curves estimating 
the probability of remaining in the study for patients treated with olanzapine or 
quetiapine.
Figure 1b (lower) Reasons for discontinuation. “Other” includes discontinuations 
due to patient incarceration.
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Other safety evaluations
Treatment-emergent adverse events (TEAEs)
No statistically signiﬁ  cant difference was observed for 
TEAEs between treatment groups. The most common TEAEs 
( 5%) in the olanzapine treatment group were sedation, 
vomiting, anxiety, hypertension, insomnia, pharyngolaryn-
geal pain, somnolence, weight decrease, and weight increase. 
In the quetiapine treatment group, the most common TEAEs 
( 5%) were sedation, anxiety, insomnia, weight increase, 
headache, constipation, dry mouth, auditory hallucination, 
paranoia, and agitation.
Discussion
In this randomized, double-blind, ﬂ  exible-dosed trial, we 
examined the potential risks and beneﬁ  ts of switching 
from olanzapine to quetiapine mentally stable obese or 
overweight patients with schizophrenia or schizoaffective 
disorder. No signiﬁ  cant difference was seen in the time to 
or incidence of psychiatric relapse using this strategy. How-
ever, signiﬁ  cant between-group differences were observed 
in the rates of study discontinuation due to any reason, due 
to psychiatric adverse events, or due to a combination of 
lack of efﬁ  cacy and psychiatric AEs (all three were higher 
in the quetiapine group), and the rates of categorical BMI 
increase (higher in the olanzapine group). No statistically 
signiﬁ  cant between-group difference was observed in the 
rates of study discontinuation due to nonpsychiatric adverse 
events. Mean changes in weight, BMI, fasting glucose, insu-
lin, HbA1c, and lipids from baseline to endpoint by LOCF 
method were generally small and did not differ signiﬁ  cantly 
between groups.
This study illustrates the importance of evaluating both 
efﬁ  cacy and safety when examining the potential effects of 
treatment changes on mentally stable patients. While most 
studies examining the potential effects of switching patients 
from olanzapine to another antipsychotic focus on metabolic 
parameters, they do not always report potential changes in 
psychiatric symptoms (Garman et al 2007). Study discontinu-
ation due to any reason is thought to serve as a measure of 
efﬁ  cacy and safety (Essock et al 2006). In this analysis, we 
found signiﬁ  cant differences in study discontinuation rates 
in favor of olanzapine, which may reﬂ  ect this composite 
measure.
The increased rate of study discontinuation in the 
quetiapine group due to lack of efficacy and occurrence 
of psychiatric events may indicate a prodromal worsen-
ing in symptoms that led to study discontinuation prior 
to relapse (as defined in this study). Overall, this finding 
suggests that switching a stable patient from olanzapine 
to another antipsychotic medication may present addi-
tional risk for treatment discontinuation, a finding that 
has been previously reported (Essock et al 2006). Alter-
natively, the fact that the quetiapine treatment group had 
a significantly higher discontinuation rate – resulting in 
a shorter duration of drug exposure – may have affected 
the analyses of relapse rate and time to relapse. Limit-
ing the interpretation is the possibility that some of the 
patients that discontinued early in the course of quetiapine 
Table 1 Relapse rate by treatment group
Relapse criteria  Olanzapine (N = 68) Quetiapine  (N  = 65) Total  (N  = 133) p  valuea
Hospitalization for psychiatric   1 (1.47%)  5 (7.69%)  6 (4.51%)  ns
reasons after Visit 2
 20% worsening in PANSS Total score   0  2 (3.08%)  2 (1.5%)  ns
and increase in Level of Care for psychiatric 
reason after Visit 2
 20% worsening on the PANSS Total score   7 (10.29%)  7 (10.77%)  14 (10.5%)  ns
and worsening of CGI-S by at least one level 
compared to baseline and CGI-S score  4
Patients meeting at least one of the above criteria  8 (11.76%)  10 (15.38%)  18 (13.5%)  ns
ap value is based on Fisher’s exact test for treatment difference.
Abbreviations: CGI-S, Clinical Global Impression of Severity; ns, not signiﬁ  cant; PANSS, Positive and Negative Syndrome Scale.
Figure 2 Time remaining relapse free. Kaplan-Meier curves estimating the probabil-
ity of remaining relapse free for patients treated with olanzapine or quetiapine.
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treatment might have done so due to eventual withdrawal 
symptoms potentially related to their prior treatment with 
olanzapine.
Our results are supported by the outcome of the CATIE 
study. There, patients who had discontinued treatment with 
the atypical antipsychotic they had been assigned to in 
phase I were randomly reassigned to olanzapine, risperi-
done, quetiapine, or ziprasidone. Direct comparison of time 
to discontinuation between all 4 groups revealed superior 
performance of olanzapine and risperidone over quetiapine 
and ziprasidone (Stroup et al 2006).
Our analysis did not detect signiﬁ  cant between-group 
differences in treatment-emergent changes in metabolic 
laboratory parameters, which is contrary to published reports 
that have reported serum lipid level decreases after switching 
from olanzapine to other antipsychotics (Montes et al 2007). 
Patients in this trial may have differed from those in previous 
studies in terms of severity and duration of illness, or the 
higher rate of study discontinuation in the quetiapine group 
may have limited the ability to detect signiﬁ  cant differences 
in LOCF analysis of changes in weight, BMI, and other 
metabolic parameters. The MMRM method, known to be 
less affected by patient dropouts (Mallinckrodt et al 2003), 
showed a signiﬁ  cantly greater increase in weight and BMI 
occurring in patients who continued receiving olanzapine 
than in those who switched to quetiapine. While the overall 
MMRM analysis revealed statistically signiﬁ  cant p values 
for weight (p = 0.020) and BMI (p = 0.035), the difference 
at last scheduled visit using this method was not signiﬁ  cant. 
For the difference in rate of BMI increase, we have to real-
ize that the exposure time in the olanzapine group is much 
higher, which makes the interpretation of this result very 
difﬁ  cult. Despite adequate power to detect signiﬁ  cant differ-
ences in several metabolic parameters, conclusions regarding 
changes in the potential risk of treatment-emergent changes 
in metabolic parameters after switching from olanzapine to 
quetiapine should be viewed with caution based on the data 
presented here. Nonetheless, the differences in weight were 
generally small, which is a ﬁ  nding similar to that reported 
by Gupta et al who observed a change in mean BMI from 
35.1 kg/m2 to 34.4 kg/m2 (p = 0.065) and a change in mean 
weight from 103 kg to 101 kg (p = 0.03) in an open-label 
study in which 16 patients were switched from olanzapine 
to quetiapine. In that study, only 12 patients completed 
treatment and 1 patient discontinued due to exacerbation 
of psychosis (Gupta et al 2004). Comparable changes in 
weight and BMI have been observed after the addition of 
metformin (Baptista et al 2007) or amantadine (Deberdt 
et al 2005) to olanzapine treatment as weight-mitigating 
agents, without increasing the risk for discontinuation due 
to increased psychiatric symptoms.
Figure 3 Repeated measures analysis of changes in PANSS Total Score. Least-squares 
means (LSMEANS) for changes in PANSS from baseline to each scheduled visit esti-
mated with a MMRM model that included terms for investigator, drug, PANSS baseline 
score, visit-by-baseline score and visit-by-drug interactions.
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Table 2 LOCF analysis of weight, BMI, and metabolic laboratory parameters
Parameter Olanzapine  (n  = 68)   Quetiapine  (n  = 65)
  Baseline  Change  p value  Baseline  Change  p value  Between-group
 (SD)  (SD)    (SD)  (SD)    p  value
Weight (kg)  100.71 (19.73)  0.99 (5.82)  0.157  106.74 (19.87)  –0.82 (5.30)  0.204  0.088
BMI  34.55 (7.14)  0.31 (1.94)  0.153  37.45 (8.57)  –0.30 (1.90)  0.205  0.150
Fasting glucose (mmol/L)  5.58 (1.56)  –0.01 (1.53)  0.622  5.36 (1.46)  –0.06 (1.08)  0.693  0.228
HbA1c (%)  5.82 (0.84)  0.07 (0.48)  0.292  5.93 (0.77)  –0.03 (0.40)  0.493  0.318
Cholsterol (mmol/L)  5.33 (1.16)  –0.20 (0.93)  0.085  5.17 (1.08)  –0.11 (0.68)  0.325  0.471
LDL (mmol/L)  3.36 (1.00)  –0.14 (0.82)  0.138  3.16 (0.95)  –0.07 (0.51)  0.243  0.981
HDL (mmol/L)  1.18 (0.31)  –0.03 (0.21)  0.487  1.26 (0.42)  –0.02 (0.18)  0.513  0.872
Insulin (uIU/ml)  23.95 (22.02)  1.78 (24.26)  0.500  30.49 (46.67)  3.62 (74.72)  0.894  0.262
Triglycerides (mmol/L)  2.1 (1.23)  –0.11 (0.98)  0.314  1.96 (1.34)  0.07 (0.90)  0.379  0.167
Abbreviations: BMI, body mass index; LOCF, last observation carried forward; SD, standard deviation.Therapeutics and Clinical Risk Management 2008:4(4) 719
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Figure 4 Changes in BMI and weight.
Figure 4a (upper) Repeated measures analysis of weight changes. Least-squares 
means (LSMEANS) for changes in weight (kg) from baseline to each scheduled visit 
estimated with MMRM model that includes terms for investigator, drug, baseline 
weight, visit-by-baseline score and visit-by-drug interactions. The vertical error bars 
indicate LSMEANS standard error.
Figure 4b (lower) Repeated measures analysis of changes in BMI. Least-squares 
means (LSMEANS) for changes in BMI (kg/m2) from baseline to each scheduled visit 
estimated with MMRM model that included terms for investigator, drug, baseline BMI, 
visit-by-baseline score, and visit-by-drug interactions. The vertical error bars indicate 
LSMEANS standard error.
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beyond this period; thus it is unlikely that the cross-titration 
regimen explains the higher rate of study discontinuations 
in the quetiapine group.
This study had several limitations. The most signiﬁ  cant 
was reduced sample size in both treatment groups. The study 
was terminated early due to slow enrollment, although the 
decision to terminate was not based on an interim analysis of 
un-blinded data, which ensures that subsequent analyses had 
no inherent selection bias. Nevertheless, termination before 
the recruitment goal was reached diminishes the power of the 
statistical analysis and substantially reduces the probability 
to detect a possible treatment difference in relapse or other 
measures of efﬁ  cacy and safety.
Further limitations were the signiﬁ  cant between-group 
differences seen at baseline for PANSS total score and BMI. 
These could have affected testing for treatment effect for 
categorical variables using Fisher’s exact test at endpoints 
that were not adjusted for these baseline differences. To 
reduce possible bias due to these imbalances, we reanalyzed 
categorical changes in weight and BMI (stratiﬁ  ed by baseline 
BMI), as well as study discontinuation due to psychiatric 
reasons and lack of efﬁ  cacy (stratiﬁ  ed by baseline PANSS 
total score) using a stratiﬁ  ed version of Fisher’s exact test. 
These reanalyzes produced very similar results with the same 
signiﬁ  cance levels as the unadjusted analysis.
In conclusion, we were able to demonstrate that switching 
from olanzapine to quetiapine in mentally stable patients can 
increase rate of study discontinuations in particular because of 
emergent psychiatric symptoms, although signiﬁ  cantly fewer 
quetiapine-treated patients experienced an increase in BMI 
and some modest weight differences in favor of the quetiapine 
arm were observed. This suggests that in general, patients 
remaining on olanzapine therapy are more likely to stay stable 
and to continue treatment compared with those switched to 
quetiapine. Therefore, treating clinicians should carefully 
evaluate the potential risk for treatment discontinuation due 
to symptom exacerbation when considering a switch from one 
antipsychotic to another in psychiatrically stable patients.
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